ISCOMs, Liposomes, and Oil-Based Vaccine Delivery Systems

Tomasi, M.

doi:10.1016/b978-012410580-5/50014-5

Search citation statements

Order By: Relevance

Paper Sections

Select...

The Iscom Particle1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1998

2007

Publication Types

Select...

Article2

Book1

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The second is essentially the same structure but without the protein, and is usually referred to as Iscom Matrix (also called ISCOMATRIX , a trademark of ISCOTEC AB) [5]. Typically, both ISCOMs and Iscom Matrix exist as spherical, hollow, rigid, cage-like particles of about 40 nm in diameter with a strong negative charge [5][6][7][8][9]. However, other structural forms including rings and aggregates can occur with properties essentially identical to the 40-nm particle.…”

Section: The Iscom Particlementioning

confidence: 99%

ISCOMs: an adjuvant with multiple functions

Sjölander

Cox

Barr

1998

Journal of Leukocyte Biology

158

View full text Add to dashboard Cite

Section: The Iscom Particlementioning

confidence: 99%

ISCOMs: an adjuvant with multiple functions

Sjölander

Cox

Barr

1998

Journal of Leukocyte Biology

158

View full text Add to dashboard Cite

Community-acquired pneumonia: paving the way towards new vaccination concepts

Becker

Guzmán

2007

Community-Acquired Pneumonia

View full text Add to dashboard Cite

A human norovirus-like particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model

Souza

Costantini

Azevedo

et al. 2007

Vaccine

View full text Add to dashboard Cite

We inoculated gnotobiotic pigs oraly/intranasally with human norovirus GII.4 HS66 strain viruslike particles (VLP) and immunostimulating complexes (ISCOM) or mutant E. coli LT toxin (mLT, R192G) as mucosal adjuvants, then assessed intestinal and systemic antibody and cytokine responses and homologous protection. Both vaccines induced high rates of seroconversion (100%) and coproconversion (75-100%). The VLP+mLT vaccine induced Th1/Th2 serum cytokines and cytokine secreting cells, whereas the VLP+ISCOM vaccine induced Th2 biased responses with significantly elevated IgM, IgA and IgG antibody-secreting cells in intestine. Nevertheless, both vaccines induced increased protection rates against viral shedding and diarrhea (75-100%) compared to controls; however, only 57% of controls shed virus.

show abstract

ISCOMs, Liposomes, and Oil-Based Vaccine Delivery Systems

Cited by 3 publications

References 77 publications

ISCOMs: an adjuvant with multiple functions

ISCOMs: an adjuvant with multiple functions

Community-acquired pneumonia: paving the way towards new vaccination concepts

A human norovirus-like particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model

Contact Info

Product

Resources

About